Trial Profile
Phase IIb trial of metadoxine in pediatric attention deficit hyperactivity disorder
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 15 Nov 2017 According to an Arcturus Therapeutics media release, Alcobra merged with Arcturus Therapeutics and the combined company is named as Arcturus Therapeutics
- 20 Feb 2015 New trial record